Update on glioma biotechnology

Clin Neurol Neurosurg. 2020 Aug:195:106075. doi: 10.1016/j.clineuro.2020.106075. Epub 2020 Jul 7.

Abstract

Neuro-oncological research is at the forefront of the rising cancer therapy market, as evidenced by its growing revenue and the multitude of clinical trials investigating innovative treatment approaches. The Feinstein Institute for Medical Research, in conjunction with the Department of Neurosurgery at Lenox Hill Hospital and the Zucker School of Medicine at Hofstra / Northwell, sponsored The Brain Tumor Biotech Summit in New York City in June 2019. The aim of the Summit was to provide a forum that encourages collaboration between cancer specialists, biotechnology and pharmaceutical industry leaders, and the investment community in order to promote innovation and advance emerging therapies for brain tumors. Areas highlighted during the Summit included immunotherapy, precision medicine, and novel applications and experimental treatments such as receptor targeting, methods for improved drug delivery, and innovative intraoperative techniques and technologies. This review synthesizes the recent breakthroughs in brain tumor research as presented at The Brain Tumor Biotech Summit.

Keywords: Biotechnology; Brain tumor; Glioblastoma; Glioma; Industry.

Publication types

  • Review

MeSH terms

  • Biotechnology*
  • Brain Neoplasms / therapy*
  • Drug Delivery Systems
  • Glioma / therapy*
  • Humans
  • Immunotherapy*